The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
Prelude to increased tariffs? The Trump administration has initiated a Section 232 investigation into pharmaceuticals and Semiconductors.
① The USA government disclosed on Monday that it has launched an investigation into the impact of imported Pharmaceuticals and Semiconductors on National Security; ② This is widely seen as a prelude to imposing tariffs on prescription drugs and Semiconductors, and it could further escalate the trade war initiated by the USA.
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Cuts Target Price to $2
B. Riley Securities Maintains Buy on Vaxart, Lowers Price Target to $2
Vaxart Analyst Ratings
71763267 : @Jaguar8 May I ask for your opinion about SOBR? I was expecting to see it on the list today..
Jaguar8 OP 71763267 : I am still finalizing my momentum plays. I will check it later
102414580 Jaguar8 OP : How about BIOATLA? got potential?
Jaguar8 OP 102414580 : ??? I don’t know of that long ticker symbol
71763267 Jaguar8 OP : Got it, thanks :)
View more comments...